Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
164 Leser
Artikel bewerten:
(0)

Melzi Surgical Appoints Financial Industry Executive, Michael Layman to Board of Directors

RENO, NV / ACCESSWIRE / January 25, 2022 / Melzi Surgical ("Melzi" or the "Company"), a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced today the appointment of Michael Layman to its Board of Directors.

"We are pleased to welcome Michael to our Board of Directors. Michael has a track record of being instrumental in the transormation of early stage life sciences companies as well more broadly. As Melzi continues to progress on multiple fronts, we believe his broad leadership, expertise and well-established network within the financial markets will be an asset of significant value. We are committed to maximizing the potential of Melzi and address a persisting unmet need for a device to locate surgical lost sharps. We look forward to our continued growth and working to unlock the full potential of the Company," commented Reid Rutherford, MBA, President of Melzi.

Mr. Layman is a well-established financial industry executive with a track record for driving value and growth for both private and publicly traded companies. Mr. Layman currently serves as General Partner/CEO of Emerald Shoals Targeted Opportunities Fund LP, a hybrid growth fund backed by a network of ultra-high net worth individuals seeking novel opportunities to invest in high-growth catalyst driven companies. In addition, he serves as the Chairman and Managing Director at LF Athens Capital. Prior to his current role at Emerald Shoals, Mr. Layman served at a large top-four brokerage house where he was co-owner of a private wealth management group where he was responsible for identifying attractive and undervalued investment opportunities. He has also aided in the development and implementation of various investment strategies based on differing types of needs from conservative to aggressive growth. Additionally, Mr. Layman previously worked for a private equity fund in New York where he established a strong network of relationships with research analysts and investment bankers at a number of Wall Street firms. He currently serves as a board member for American Resources Corporation, Land Betterment Corporation and Clarametyx Biosciences. Mr. Layman obtained his Bachelor of Arts degree in business from Otterbein University.

"Melzi has positioned itself to be a potentially pivotal player in the medical device industry. Hospitals, physicians, and patients are in serious need for a solution when it comes to lost surgical sharps. I am excited to join the team at Melzi to help optimize its potential and build value across all stakeholders," added Mr. Layman.

About Melzi Surgical

Melzi is a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses. The Company's lead product, the Melzi Sharps Finder, is a U.S. FDA registered device designed to locate instruments, needles, broken pieces and fragments, or sharp objects ("sharps") that have been lost inside a patient during surgery. The Melzi Sharps Finder is an easy-to-use hand tool capable of working in a 5mm trocar for laparoscopic and robotic surgeries and can also be used in open surgery. In a lab study, testing results with the Melzi Sharps Finder show detection of 13mm, 17mm, and 26mm needles with a 95% reliability rate.

The use of an adjunct technology, like the Melzi Sharps Finder, can bring patient safety, time, financial, and risk benefits. The Melzi Sharps Finder is currently indicated for use in gastroenterology and urology surgeries.

For more information about the Company, please visit melzisurgical.com

Investor Contact:

Jenene Thomas, JTC Team
T: (US): +1 (833) 475-8247
E: melzi@jtcir.com

Business Development Contact:

Allen McClinton, Melzi Surgical
T: 650-272-8987
E: allen@melzicorp

SOURCE: Melzi Surgical



View source version on accesswire.com:
https://www.accesswire.com/685284/Melzi-Surgical-Appoints-Financial-Industry-Executive-Michael-Layman-to-Board-of-Directors

© 2022 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.